Abstract: Amongst the genetic mutations resistant to NNRTIs, G190S mutation was the highest (51.2%), K101HQ mutation was 39.5% and Y181I mutation was 34.9%.
Result: Amongst the genetic mutations resistant to NNRTIs, G190S mutation was the highest (51.2%), K101HQ mutation was 39.5%, and Y181I mutation was 34.9% (Table 3).
Table: K101Q
Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.
PMID: 30079168
2018
Journal of public health in Africa
Result: G190A and K101Q/E were more frequent in mothers (16.67% and 16.67% respectively) than in infants (5.56% and 5.56%) and conferred resistance to NVP and EFV.
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
PMID: 29977795
2018
African journal of laboratory medicine
Discussion: The H221Y mutation could also impact clinical outcomes as Y181C/H221Y along with the K103N or K101Q mutations could increase resistance levels to nevirapine over 100-fold (K103N) or 3000-fold (K101Q).
Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.
Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY(R) System.
Abstract: In terms of loci, the detection rate of the alleles was greater than 97% for M41L, K65R, M184V and G190A, 91.2% for K101E/Q/P, 91.2% for T215F/Y, 89.9% for K103N/S and 80.5% for L210W.
Introduction: In this study, we established a multiplex assay for detecting the drug resistance mutations at 8 loci (M41L, K65R, K101E/Q/P, K103N/S, M184V, G190A, L210W and T215F/Y), which are as
Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
PMID: 26651266
2016
AIDS research and human retroviruses
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I, V108I, E138S, V179D/E/F/I/T, Y181F/G/S, Y188F, V189I, G190A/C/E/Q/S/T/V, and M230V
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
Result: According to the HIV Drug Resistance Database (http://hivdb.stanford.edu/), K101Q, E138Q and exchanges at position V179 are also detected in patients treated with EFV.
The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.
Method: M46I, I54V, V82A, M46IN88S, G48VI54V, M46IV82TI84V, and G48VI54VV82A mutations were introduced into the PR coding region, and K103N, Y181C, K103NY181C, K101Q, K101QY181C, K101QH221Y, PMID: 27120449
2016
PloS one
Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,
HIV mutation literature information.
PMID: 
2019
Infection and drug resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT